Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLPG NASDAQ:KNSA NASDAQ:SBTX NASDAQ:SUPN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLPGGalapagos$30.40+1.8%$27.96$22.36▼$31.23N/A0.07251,689 shs185,272 shsKNSAKiniksa Pharmaceuticals International$28.84+0.1%$27.69$17.82▼$30.69$2.10B0.05555,940 shs160,004 shsSBTXSilverback Therapeutics$16.95-0.8%$14.97$2.80▼$8.97$611.18M0.6337,931 shs1.30 million shsSUPNSupernus Pharmaceuticals$33.70+3.1%$32.24$26.65▼$40.28$1.89B0.7484,898 shs401,709 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLPGGalapagos+3.61%+4.55%+6.27%+25.53%+13.71%KNSAKiniksa Pharmaceuticals International+5.84%+4.96%-5.04%+54.42%+42.36%SBTXSilverback Therapeutics-0.82%+5.34%+16.98%+27.06%+73.67%SUPNSupernus Pharmaceuticals+1.81%+1.87%-1.80%+5.15%+22.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGLPGGalapagos0.3352 of 5 stars0.83.00.00.01.30.00.6KNSAKiniksa Pharmaceuticals International3.4517 of 5 stars3.54.00.00.02.13.30.6SBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASUPNSupernus Pharmaceuticals2.0159 of 5 stars1.22.00.04.13.20.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLPGGalapagos 1.50Reduce$25.33-16.65% DownsideKNSAKiniksa Pharmaceuticals International 3.00Buy$39.3336.41% UpsideSBTXSilverback Therapeutics 0.00N/AN/AN/ASUPNSupernus Pharmaceuticals 2.33Hold$36.006.83% UpsideCurrent Analyst Ratings BreakdownLatest SBTX, KNSA, SUPN, and GLPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025KNSAKiniksa Pharmaceuticals InternationalWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $42.004/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.004/16/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLPGGalapagos$298.31MN/A$0.77 per share39.68$47.57 per shareN/AKNSAKiniksa Pharmaceuticals International$481.17M4.37N/AN/A$6.60 per share4.37SBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/ASUPNSupernus Pharmaceuticals$661.82M2.85$4.38 per share7.69$18.76 per share1.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLPGGalapagos$80.16MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M-$0.25N/A115.34N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)SBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/ASUPNSupernus Pharmaceuticals$73.86M$1.1130.3423.40N/A9.27%12.23%9.17%8/5/2025 (Estimated)Latest SBTX, KNSA, SUPN, and GLPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025SUPNSupernus Pharmaceuticals$0.47N/AN/AN/A$154.06 millionN/A7/23/2025Q2 2025GLPGGalapagos-$0.34N/AN/AN/A$80.13 millionN/A7/22/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.08N/AN/AN/AN/AN/A4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals International$0.02$0.11+$0.09$0.11$128.35 million$137.79 million4/23/2025Q1 2025GLPGGalapagos-$0.23-$2.47-$2.24-$2.45$72.22 million$97.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGLPGGalapagosN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLPGGalapagosN/A7.957.86KNSAKiniksa Pharmaceuticals InternationalN/A3.663.43SBTXSilverback TherapeuticsN/A67.8767.87SUPNSupernus PharmaceuticalsN/A2.442.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLPGGalapagos32.46%KNSAKiniksa Pharmaceuticals International53.95%SBTXSilverback Therapeutics74.89%SUPNSupernus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipGLPGGalapagos2.91%KNSAKiniksa Pharmaceuticals International53.48%SBTXSilverback Therapeutics34.40%SUPNSupernus Pharmaceuticals8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLPGGalapagos1,310N/AN/AOptionableKNSAKiniksa Pharmaceuticals International22072.97 million33.95 millionOptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableSUPNSupernus Pharmaceuticals58055.99 million51.06 millionOptionableSBTX, KNSA, SUPN, and GLPG HeadlinesRecent News About These Companies2 Cash-Heavy Stocks to Own for Decades and 1 to Approach with CautionJuly 10 at 9:41 AM | finance.yahoo.comBranded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)July 9 at 5:15 AM | msn.comHead-To-Head Analysis: Supernus Pharmaceuticals (NASDAQ:SUPN) & Personalis (NASDAQ:PSNL)July 5, 2025 | americanbankingnews.comMeritage Portfolio Management Acquires 10,622 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)July 4, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (SUPN) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.com8,151 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Robeco Institutional Asset Management B.V.July 3, 2025 | marketbeat.comSage Sacks Entire Staff After Supernus BuyoutJune 30, 2025 | biospace.comBSupernus Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst QuestionsJune 27, 2025 | msn.comSupernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five yearsJune 23, 2025 | uk.finance.yahoo.comSupernus Pharmaceuticals (NASDAQ:SUPN) Lowered to Hold Rating by Wall Street ZenJune 21, 2025 | marketbeat.comSAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGEJune 18, 2025 | businesswire.comSupernus Pharma to Buy Sage Therapeutics for Up to $795 MillionJune 16, 2025 | marketwatch.comSupernus enters depression drug market with up to $795 million Sage dealJune 16, 2025 | msn.comSupernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage TherapeuticsJune 16, 2025 | msn.comSupernus to acquire depression drugmaker SageJune 16, 2025 | msn.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.June 16, 2025 | prnewswire.comSupernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M DealJune 16, 2025 | gurufocus.comSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry ...June 16, 2025 | gurufocus.comSupernus Pharmaceuticals to Acquire Sage Therapeutics in a Strategic Move | SUPN stock newsJune 16, 2025 | gurufocus.comSage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know.June 16, 2025 | barrons.comSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry ...June 16, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSBTX, KNSA, SUPN, and GLPG Company DescriptionsGalapagos NASDAQ:GLPG$30.40 +0.55 (+1.83%) As of 02:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Kiniksa Pharmaceuticals International NASDAQ:KNSA$28.84 +0.04 (+0.12%) As of 02:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Silverback Therapeutics NASDAQ:SBTX$16.95 -0.14 (-0.82%) As of 07/8/2025Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Supernus Pharmaceuticals NASDAQ:SUPN$33.70 +1.03 (+3.14%) As of 02:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Boeing's Rebound Is Well Underway—But Is It Too Late? Why Microsoft Keeps Showing Up in Congressional Portfolios Buffett's $2B+ Bet With Big Long-Term Potential Just Got Upgraded Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
